Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GILTERITINIB Cause Electrocardiogram qt prolonged? 112 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 112 reports of Electrocardiogram qt prolonged have been filed in association with GILTERITINIB (Xospata). This represents 3.1% of all adverse event reports for GILTERITINIB.

112
Reports of Electrocardiogram qt prolonged with GILTERITINIB
3.1%
of all GILTERITINIB reports
39
Deaths
56
Hospitalizations

How Dangerous Is Electrocardiogram qt prolonged From GILTERITINIB?

Of the 112 reports, 39 (34.8%) resulted in death, 56 (50.0%) required hospitalization, and 22 (19.6%) were considered life-threatening.

Is Electrocardiogram qt prolonged Listed in the Official Label?

Yes, Electrocardiogram qt prolonged is listed as a known adverse reaction in the official FDA drug label for GILTERITINIB.

What Other Side Effects Does GILTERITINIB Cause?

Acute myeloid leukaemia (366) Febrile neutropenia (346) Off label use (334) Platelet count decreased (327) Pneumonia (302) Myelosuppression (300) Pyrexia (281) Death (206) Product use issue (189) Hepatic function abnormal (181)

What Other Drugs Cause Electrocardiogram qt prolonged?

QUETIAPINE (1,869) OLANZAPINE (1,325) RIBOCICLIB (1,020) AMIODARONE (1,000) HYDROXYCHLOROQUINE (992) CLOZAPINE (958) CITALOPRAM HYDROBROMIDE (917) ESCITALOPRAM OXALATE (899) ONDANSETRON (881) BUPROPION (853)

Which GILTERITINIB Alternatives Have Lower Electrocardiogram qt prolonged Risk?

GILTERITINIB vs GIMERACIL\OTERACIL\TEGAFUR GILTERITINIB vs GINKGO GILTERITINIB vs GIVINOSTAT GILTERITINIB vs GIVOSIRAN GILTERITINIB vs GLASDEGIB

Related Pages

GILTERITINIB Full Profile All Electrocardiogram qt prolonged Reports All Drugs Causing Electrocardiogram qt prolonged GILTERITINIB Demographics